テキサスにおける軟部組織肉腫の臨床試験
テキサス内の拠点で、軟部組織肉腫に関する38件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07189871Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
- UT MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06498648A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center, Dallas
- Baylor College of Medicine, Houston
被験者募集中第1/2相
25歳以下 · 全性別 · 2026/09/25更新 · NCT04094610Anti-GD2 ADC M3554 in Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06641908A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07705334First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
- University Of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06797999Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/08更新 · NCT05732831Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- UT MD Anderson Cancer Center, Houston
被験者募集中第1相
12歳〜85歳 · 全性別 · 2026/09/08更新 · NCT03715933Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
- UT MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT05711615A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06760819Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/09/02更新 · NCT05334069Actinium Therapy for Late-stage Aggressive Sarcomas
- MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07156565STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
- MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
- NEXT Dallas, Irving
- 他2件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT06975293Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- M D Anderson Cancer Center, Houston
被験者募集中観察研究
全年齢 · 全性別 · 2026/08/21更新 · NCT01772771Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
- MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07283731T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
- MD Anderson Cancer Center, Houston
被験者募集中第1相
12歳以上 · 全性別 · 2026/08/18更新 · NCT06474676Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
- Ut Southwestern Medical Center, Dallas
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/17更新 · NCT07139990A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06242470Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
- M D Anderson Cancer Center, Houston
被験者募集中
10歳以上 · 全性別 · 2026/08/11更新 · NCT04199026A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
- The University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第1相
1歳〜30歳 · 全性別 · 2026/08/06更新 · NCT07444619IDOV-Immune for Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06910657Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
- MD Anderson Cancer Center, Houston
被験者募集中観察研究
18歳以上 · 全性別 · 2026/07/15更新 · NCT07377747Lead-212 PSV359 Therapy for Patients With Solid Tumors
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳〜90歳 · 全性別 · 2026/07/06更新 · NCT06710756Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/11更新 · NCT04771520A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/11更新 · NCT06789172A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/05/27更新 · NCT03093116SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
- The University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/22更新 · NCT07049848Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
- M.D. Anderson Children's Cancer Hospital, Houston
被験者募集中第2相
8歳〜30歳 · 全性別 · 2026/05/22更新 · NCT05726383Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma
- William Beaumont Army Medical Center, Fort Bliss
被験者募集中
18歳以上 · 全性別 · 2026/05/15更新 · NCT06129903A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/15更新 · NCT04969835Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
- M D Anderson Cancer Center, Houston
被験者募集中
18歳以上 · 全性別 · 2026/04/15更新 · NCT04693377Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Children's Health Dallas, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
2歳〜30歳 · 全性別 · 2026/02/03更新 · NCT05734066HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
- Texas Children's Hospital, Houston
被験者募集中第1相
1歳〜25歳 · 全性別 · 2026/01/22更新 · NCT04995003cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Elligo Health Research, Inc., Austin
被験者募集中観察研究健康なボランティア歓迎
40歳以上 · 全性別 · 2026/01/20更新 · NCT05366881A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/12/11更新 · NCT06943521A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- Mary Crowley Cancer Research, Dallas
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/10/08更新 · NCT04370587BostonGene and Exigent Genomic INsight Study
- Oncology Consultants, Houston
被験者募集中観察研究
18歳以上 · 全性別 · 2025/02/17更新 · NCT06272864ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。